4CPS-082 Detection of medication errors and unmet needs of oncology patients during the oncology pharmacy practice visit

<h3>Background and Importance</h3> Medication errors in oncology patients are of utmost importance because oral antineoplastic drugs have a narrow therapeutic margin, complex dosing regimens and interactions with other drugs. <h3>Aim and Objectives</h3> Detect medication errors and other patient needs from a holistic view in oncology pharmacy practice. <h3>Material and Methods</h3> Prospective observational study of oncology patients in a tertiary hospital for 2 years. Demographic variables such as sex, age, pathology, chemotherapy and home treatment were collected. The types of patient errors or needs were categorised and recorded using an Excel database. Pharmaceutical interventions were carried out with the patient and recorded in the clinical history in the Diraya Clínica programme. <h3>Results</h3> Total of 100 patients. The 69.5% men and 30.5% women, median age 67 years. The most frequent oncologic pathologies: prostate cancer (54%), breast (40%), colon (25%), lung (18%), renal (10%), ovarian (7%), brain tumours (5%) and endometrial cancer (3%). The most frequent chemotherapeutic treatments: abiraterone (23%), capecitabine (15%), abemaciclib (14%), Trifluridine Typiracil (13%), enzalutamide (12%), regorafenib (11%), cabozantinib (10%), olaparib (8%), apalutamide (7%), denosumab (6%), procarbazine (5%), temozolamide (5%), capmatinib (4%), lenvatinib (3%), osimertinib (3%), alectinib (2%), erlotinib (1%). 45% patients had medication errors in the antineoplastic dose, 25% had relevant interactions with the home medication, 18% had incidents with home medication (therapeutic duplications or forgotten prescriptions), 15% requested information on the consumption of phytosanitary products, 11% needed more information on their chemotherapy treatment and 6% on their pathology after leaving the oncology clinic. A lack of adherence was detected in 6% and relevant adverse effects in 5%. The most frequent dose errors were: erroneous adjustment of renal function (45%), failure to reflect the dose in the patient‘s clinical history (30%), non-adjustment in hepatic insufficiency (18%) and erroneous adjustment to body surface area (12%). In 100% of the patients, pharmaceutical interventions were carried out jointly with the oncology team in order to increase patient information and avoid medication errors. All of them were recorded in the patient‘s clinical history. <h3>Conclusion and Relevance</h3> Joint interventions between the pharmacy and oncology teams have proven to be an effective tool to contribute to the achievement of therapeutic goals and patient safety. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest